Erlotinib treatment induces cytochrome P450 3A activity in non‐small cell lung cancer patients

AIMS: Erlotinib is a tyrosine kinase inhibitor used in the treatment of non‐small cell lung cancer highly metabolized by the cytochrome P450 (CYP) 3A. Hence, CYP3A4 activity might be a useful predictor of erlotinib pharmacokinetics in personalized medicine. The effect of erlotinib on CYP3A activity...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Clin Pharmacol
Auteurs principaux: Svedberg, Anna, Vikingsson, Svante, Vikström, Anders, Hornstra, Niels, Kentson, Magnus, Branden, Eva, Koyi, Hirsh, Bergman, Bengt, Gréen, Henrik
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624433/
https://ncbi.nlm.nih.gov/pubmed/30945322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13953
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires